Summary
In this short article for an Australian nursing magazine, New Zealand mental health nurse Jason Watson challenges the idea that withholding gender-affirming treatment from young people drives them to suicide. He looks at six large, long-term studies from the Netherlands, Sweden, Denmark, the UK and Finland. In his reading, suicide rates among transgender people stayed well above the general population after treatment, rates fell over time only for trans women in one Dutch study, and the Tavistock clinic review found no rise in youth suicides after access to puberty blockers was restricted in England. He concludes that the 'transition or suicide' claim is weak at best. The article was printed in July 2026, then removed from the journal's website after complaints; the nurses' union apologised for publishing it but later said this did not imply misconduct by the author. It is an opinion piece, not a systematic review: it picks a handful of studies, most of them about adults, and some of its readings go further than the studies' own authors. For example, the Finnish study it relies on most concluded that suicide risk was explained by mental illness and that gender reassignment did not change suicide risk either way.
Key findings
- Watson 質疑一種廣為流傳的說法,即無法獲得性別肯定治療的年輕人自殺風險較高;WPATH 和美國衛生官員都曾提出這種說法。
- 他檢視了來自荷蘭、瑞典、丹麥、英國和芬蘭的六項長期追蹤研究,樣本從 324 人到超過 15,000 人,追蹤時間從 5 年到 46 年不等。
- 他指出,跨性別者在接受治療後,自殺率和死亡率仍高於一般人群,而且只有一項荷蘭研究發現跨性別女性的自殺率隨時間下降。
- 他特別提到對英格蘭 Tavistock 診所自殺事件的檢討:該檢討發現有 12 起自殺,且在青春期阻斷劑受到限制後,青少年自殺並未增加,與先前預測的激增不同。
- 他的結論是,「要轉換性別,否則就自殺」的說法「至少站不住腳,最糟則根本是錯誤的」,這與卡斯報告(Cass Review)認為該領域大多數研究品質不佳的結論一致。
- 澳洲護理師工會於 2026 年 7 月將該文從期刊網站移除,並為刊登此文致歉,後來澄清這並不代表認定作者有不當行為。
Abstract
This short article examines the narrative that trans youth who are not provided with gender-affirming healthcare face an increased risk of suicide, a view stated by WPATH's Standards of Care 8 and the US Assistant Secretary for Health in 2022. Noting the Cass Review's finding that research in this field is of poor quality, the author summarises six long-term follow-up studies from the Netherlands (Wiepjes 2020; de Blok 2021), Sweden (Dhejne 2011), Denmark (Erlangsen 2023), England (Appleby 2024, a review of suicides among Tavistock gender clinic patients) and Finland (Ruuska 2024), with sample sizes from 324 to 15,032 and follow-up from five to 46 years, and describes what each reported about suicide and mortality.
Conclusion
Only one finding, the decline in suicide among trans women over time in Wiepjes (2020), appeared to support the narrative that lack of access to gender-affirming care increases suicide risk. The author argues the other studies showed no evidence that treatment reduced suicidal behaviour, and reported higher 'other' mortality after treatment, and that Ruuska (2024), the only study with a matched control group, found much higher suicide and overall mortality among trans people. He concludes the 'trans suicide narrative' is 'at least tenuous and at most simply incorrect', consistent with the Cass Review's view that most research in this field is of poor quality.